

A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system

Su-Jun Lee ^{1,2}, Ilse P van der Heiden¹, Joyce A Goldstein, Ron HN van Schaik

Human Metabolism Section (S.J.L., J.A.G.), Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, DHHS, Research Triangle Park, NC 27709, USA and

Department of Clinical Chemistry (I.P.H., R.H.N.S.), Erasmus MC, Dr

Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

Running Title Page

a) Running Title: A new CYP3A5 variant allele: *CYP3A5*11*

b) Corresponding Author: Ron van Schaik, Department of Clinical Chemistry,

Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands

Phone: +31-10-4633119, Fax: +31-10-4367894

Email: r.vanschaik@erasmusmc.nl

c) Number of: Text pages: 25

References : 39

Tables: 1

Figures: 4

Number of words: Abstract: 215

Introduction: 612

Discussion: 805

d) Abbreviations: CYP, cytochrome P450; Reductase, NADPH-cytochrome P450 oxidoreductase, PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SNP, single nucleotide polymorphism; HPLC, high performance liquid chromatography; cDNA, complementary deoxyribonucleic acid; ALA, δ -aminolevulinic acid; and Ni-NTA, Nickel-nitrilotriacetic acid.

Abstract

A new *CYP3A5* variant, *CYP3A5*11*, was found in a single white European by DNA sequencing. The *CYP3A5*11* allele contains a single nucleotide polymorphism (SNP) (g.3775 A>G) in exon 2 which results in a Tyr53Cys substitution and a g.6986A>G splice change, the latter SNP previously reported in the defective *CYP3A5*3* allele. However, the *CYP3A5*3* is not a null allele because this variant is associated with leaky splicing, resulting in small amounts of functional protein still being produced. We therefore constructed a cDNA coding for the newly identified CYP3A5.11 protein by site-directed mutagenesis, expressed it in *Escherichia coli* and partially purified it. While bacteria transformed with wild-type *CYP3A5*1* cDNA expressed predominantly cytochrome P450, those transfected with *CYP3A5*11* expressed a significant amount of denatured cytochrome P420 in addition to cytochrome P450, suggesting the protein to be unstable. CYP3A5.11 exhibited a 38% decrease in the V_{max} for nifedipine metabolism, a 2.7-fold increase in the K_m , and a 4.4-fold decrease in the CL_{int} of nifedipine compared with CYP3A5.1. A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) genotyping procedure was developed, and used to genotyping DNA of 500

white individuals for *CYP3A5*11*. No additional examples of this allele were identified. In summary, individuals carrying the rare *CYP3A5*11* allele are predicted to have lower metabolism of CYP3A5 substrates than individuals expressing *CYP3A5*3*.

Introduction

Cytochrome P450s (CYPs) metabolize endogenous and xenobiotic compounds to more water-soluble products that are easily eliminated from the body. CYP3A is the most abundant cytochrome P450 subfamily in human liver and intestine (Watkins et al., 1987; Kolars et al., 1992; Kolars et al., 1994; Shimada et al., 1994), accounting for 30% of total P450 in the human liver, and metabolizes approximately 50% of currently used clinical drugs (Shimada et al., 1994; Guengerich, 1999; Rendic, 2002). There are four human *CYP3A* genes: *CYP3A4*, *CYP3A5*, *CYP3A7* and *CYP3A43*. In postnatal human liver, *CYP3A4* and *CYP3A5* are the two major *CYP3A* enzymes, which have overlapping substrate specificities (Guengerich, 1999; Lamba et al., 2002; Lee and Goldstein, 2005). The *in vivo* observed variability in clearance of *CYP3A*-drugs can be caused by inhibition, induction, co-medication and/or the inheritance of *CYP3A* variant alleles encoding enzymes with altered activity (Thummel and Wilkinson, 1998). The *CYP3A5* protein expression is highly variable in human liver due largely to the high frequency of an intronic SNP, *CYP3A5**3 (g.6986A>G), which creates a cryptic splice site which results in aberrant splicing (Kuehl et al., 2001). Although *CYP3A5* may represent 50% of the total

CYP3A content in livers of individuals homozygous for *CYP3A5*1*, CYP3A5 protein is detected at appreciable levels in only 10-30% of Caucasian and Asian livers due to the high frequency of *CYP3A5*3* (Kuehl et al., 2001). In contrast, CYP3A5 is highly expressed in livers of 50% of African-Americans, who have a high incidence of the *CYP3A5*1* allele (Kuehl et al., 2001). CYP3A5 is also expressed in extra hepatic tissues, such as lung (Kivisto et al., 1996), kidney (Schuetz et al., 1992; Haehner et al., 1996), breast and leukocytes (Huang et al., 1996; Janardan et al., 1996). The extent to which CYP3A5 contributes to total CYP3A activity has been a matter of debate, and ranges from accounting for up to 50% of total CYP3A protein in the liver (Kuehl et al., 2001) to being only a minor contributor (Westlind-Johnsson et al., 2003). However, the fact that plasma concentration and dose requirement of the CYP3A-metabolized immunosuppressive drug tacrolimus was clearly demonstrated to be correlated to the presence of the *CYP3A5*3* allele (Hesselink et al., 2003; Thervet et al., 2003; Haufroid et al., 2004), this demonstrates that CYP3A5 activity is important for the metabolism of specific drugs. Many additional *CYP3A5* SNPs have been described in recent reports (Lee et al., 2003; Saeki et al., 2003; Solus et al., 2004). Although *CYP3A5*3/*3* individuals have low expression of CYP3A5

protein (Kuehl et al., 2001; Lin et al., 2002), livers of these individuals contain also normally spliced RNA next to abnormally spliced RNA due to leaky splicing (Kuehl et al., 2001; Lin et al., 2002). This results in expression of some CYP3A5 protein, although at much lower amounts than in individuals containing the *CYP3A5*1* allele (Hustert et al., 2001). The *CYP3A5*3* allele has been associated with reduced clearance of lipid-lowering drugs such as simvastatin and lovastatin, as well as midazolam and tacrolimus (Hesselink et al., 2003; Thervet et al., 2003, Haufroid et al., 2004; Goto et al., 2004; Kivisto et al., 2004; Wong et al., 2004). Although several other *CYP3A4* and *CYP3A5* alleles are predicted to be defective *in vitro*, a clear association between *CYP3A* genotypes and clinical phenotype remains unclear, largely because of the overlap in substrate specificity of *CYP3A4* and *CYP3A5*. To date, the association between *CYP3A4* and *CYP3A5* genotype and variability in metabolism of *CYP3A* substrates remains an area of active study. The addition of a new allele, *CYP3A5*11* (characterized by the g.3775 A>G SNP), to the total known *CYP3A4* and *CYP3A5* alleles may be helpful in understanding these individual variations in future clinical studies.

Materials and Methods

Materials

Reduced form β -nicotinamide adenine dinucleotide phosphate (NADPH) nifedipine, δ -aminolevulinic acid (ALA), sodium cholate, phenylmethylsulfonyl fluoride (PMSF), leupeptin, aprotinin, lysozyme, ampicillin, L- α -dilauroyl-sn-glycero-3-phosphocholine, L- α -dioleoyl-sn-glycero-3-phosphocholine, and bovine brain phosphatidylserine were purchased from Sigma Chemical Co. (St. Louis, USA). Restriction enzymes and T4 DNA ligase were from New England Biolabs (Beverly, MA, USA). Oligonucleotide primers were obtained from Sigma Genosys (Woodlands, TX, USA). QuickChange mutagenesis kit and a proofreading Pfu DNA polymerase were from Stratagene (La Jolla, CA, USA). *E. coli* DH5 α competent cells and isopropyl β -D-thiogalactopyranoside (IPTG) were from Invitrogen (Boston, MA, USA). Ni-NTA affinity resin was from Qiagen (Valencia, CA, USA). Imidazole was purchased from Calbiochem (La Jolla, CA, USA). Human NADPH-cytochrome P450 oxidoreductase (P450 reductase) and cytochrome b₅ were from Oxford Biomedical Research (Oxford, MI, USA). All other chemicals and organic solvents for HPLC were of the highest grade from commercial sources.

Identification of *CYP3A5*11*

DNA samples were from 500 healthy white Dutch individuals isolated as reported previously (van Schaik et al., 2002). The study was approved by the Medical Ethical Committee of the University Hospital Rotterdam.

Construction, Expression, and Purification of *CYP3A5.11*

Wild type *CYP3A5* cDNA was kindly provided by Dr. Frank Gonzales (National Cancer Institute, National Institutes of Health). The first eight amino acids in the N-terminus of *CYP3A5*1* cDNA were modified to MALLLAVF as described for the 17-alpha hydroxylase (Barnes et al., 1991) and a 5XHis-tag was added to the C-terminal region. Primers for the N- and C-terminal modifications were described previously (Lee et al., 2003). The modified *CYP3A5* cDNA was cloned into the pCW vector via *Nde*I and *Hind*III sites and then utilized as the template for mutagenesis using a QuickChange kit (Stratagene, La Jolla, CA, USA). Mutagenesis primers for the construction of *CYP3A5*11* cDNA were 5'-ggaaatgtttgtcctgtcgtcaggtgagttg-3' (forward) and 5'-caactcacctgacgacaggacaaaacatttcc-3' (reverse). After construction, the entire *CYP3A5*11* cDNA construct was analyzed by sequencing in both directions.

Expression of CYP3A5 wild type and CYP3A5.11 proteins in *E. coli* DH5 α competent cells was induced with 0.5 mM IPTG and 0.5 mM δ -ALA and incubation proceeded at room temperature for 96 hr. To determine an optimal condition for maximal cytochrome P450 expression, CO difference spectra were monitored from 24 hr to 96 hr using a DW-2000/OLIS Spectrophotometer. Purification of P450 proteins was performed as previously described (Lee et al., 2003; Lee et al., 2005). To minimize inter-experimental variations in expression and purification, *CYP3A5* wild-type and *CYP3A5*11* cDNA constructs were simultaneously expressed, solubilized by sonication with detergent, and purified under the same conditions twice. Two sets of purified recombinant P450s were used to verify results. To increase the purity and the recovery of cytochrome P450, solubilized membrane extract was purified on Ni-NTA affinity columns utilizing a histidine-tag. The eluted P450 was dialyzed for 48 hrs in dialysis buffer (100 mM potassium phosphate, pH 7.4 and 20% glycerol) and cytochrome P450 content was measured on a DW-2000/OLIS Spectrophotometer.

Reconstitution and Enzyme Assays

The ratio of P450:P450 reductase:cytochrome b₅ was 1:4:2 as optimized previously (Lee et al., 2003). Enzyme activity was reconstituted with incubation mixtures containing 4 pmol of P450 (determined spectrally), human NADPH-cytochrome P450 oxidoreductase (16 pmol), cytochrome b₅ (8 pmol), 1:1:1 ratio of lipid mix (2 µg/reaction), sodium cholate (0.05 µmoles/reaction), and MgCl₂ (30 mM in final) in a total reaction volume of 0.1 ml in 50 mM potassium buffer, pH 7.7. Nifedipine was protected from light during the experiment. Nifedipine concentrations for the kinetic analyses were 10, 20, 40, 60, 120, 240, and 480 µM. These substrate concentrations were above the lower limit of HPLC detection (6.25 µM) and were within the linear range for enzyme activity. Reactions were pre-incubated for 3 min at 37 °C and initiated with NADPH (1 mM in final) at 37 °C for 10 min. All assays were performed in triplicate. The reactions were stopped with the addition of 50 µl methanol and vigorously vortexed for 2 min followed by centrifugation at 10,000 x g for 15 min. The oxidized metabolite in the supernatant was analyzed by HPLC as described earlier (Lee et al., 2003). There was no catalytic activity in the absence of NADPH.

Development of a Genotyping Test

A specific PCR-RFLP test was developed to detect this novel mutation. For a 50 μ l PCR, 10 ng of genomic DNA was incubated in a PCR mixture containing 1X buffer [10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl₂, 50 mM KCl, 10 mg/L gelatin (Perkin-Elmer)], 0.2 mM each of the deoxynucleotide triphosphates (Roche), 1.25 U of Amplitaq Gold (Perkin-Elmer), and 40 pmol of primers P1 (5'-CATATTACCTCCCTCTgTcGAC-3') and P2 (5'-CTCAAGCAACTCACCTGtCG). The underlined, lower case nucleotides are mismatches with the *CYP3A5* sequence, creating restriction sites in the PCR product for the detection of the *CYP3A5**11 SNP, but also creating an internal control for the digestion. PCR conditions were: 7 min at 94 °C; 30 cycles of 1 min at 94 °C, 1 min at 55 °C and 1 min at 72 °C; and finally 7 min at 72 °C. The size of the amplified product was 213 bp. The PCR product (10 μ l) was digested with Sall (New England Biolabs) in a total volume of 15 μ l for 2 h at 37°C and subsequently analyzed on a 3% agarose/Tris-borate-EDTA gel with ethidium bromide staining. The fragments obtained for the wild type allele were 196 and 17 bp; for the *CYP3A5**11 variant allele the expected fragments are 175, 21 and 17 bp. The sample identified as a heterozygote *CYP3A5**11 by sequencing was

used as a positive control for the PCR-RFLP.

Analysis of Enzyme kinetics and statistics

Nifedipine oxidation was analyzed by nonlinear regression using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA, USA). The goodness of fit was determined by the degrees of freedom, absolute sum of squares, and the standard error of the parameter estimates. Kinetics for nifedipine metabolism followed the Michaelis-Menten equation for hyperbolic kinetics as the best fit of the data as previously described (Williams et al., 2002; Lee et al., 2003). Values represent the mean \pm S.E of at least two independent experiments, each in triplicate. Statistical significance ($p < 0.001$) was determined using a two-tailed Student's t-test.

Results

We found a novel SNP while validating a wild type sample for our *CYP3A5**8 PCR-RFLP assay by sequencing DNA samples from healthy Caucasians. One sample showed a heterozygous peak at a different site than expected for the *CYP3A5**8 polymorphism. The sample was resequenced (in both directions) to confirm the presence of the newly discovered g.3775 A>G SNP (Fig.1). Analysis of this sample for the intronic *CYP3A5**3 SNP (van Schaik et al., 2002) revealed that this individual was homozygous for a g. 6986A>G SNP associated with the *CYP3A5**3/*3, allele. Subsequent sequencing of all *CYP3A5* exons in both directions indicated that no other *CYP3A5* SNPs were present (results not shown).

Maximal expression obtained for wild type *CYP3A5.1* was 100-150 nmol/liter in *E. coli*. at 72 hr. *CYP3A5.11* exhibited approximately 50% lower P450 expression of 40-70 nmol/liter at 72 hr with an additional peak at 420nm, suggesting that the protein may be unstable. *CYP3A5.1* protein did not contain a 420 nm peak at 72 hr of expression in *E. coli*. Purification of P450s by Ni-NTA affinity column through the histidine-tag resulted in approximately 40% recovery for wild type and ~10% recovery for *CYP3A5.11*. Purified *CYP3A5.1* protein

contained only a small peak at 420nm, but CYP3A5.11 protein exhibited comparable amounts of denatured cytochrome P420 and cytochrome P450 despite two different rounds of expression and purification (Fig.2). For enzyme assays, the reaction was normalized to equal amounts of cytochrome P450, not cytochrome P420. Since kinetic analysis requires large amounts of enzyme, we initially compared the statistical differences in turnover number by two aliquots of CYP3A5.1 and CYP3A5.11 proteins purified on separate days at two different concentrations of substrate. The first concentration of nifedipine, 60 μ M, approximates the K_m value of wild-type CYP3A5 as determined in our laboratory, and the second higher concentration of 240 μ M approaches the V_{max} of the enzyme. Fig. 3 shows the results of two independent sets of assays. CYP3A5.11 had significantly lower (67% and 70% ($P < 0.001$)) turnover numbers for oxidation of nifedipine at the low substrate concentration and 44% and 50% ($P < 0.001$) lower activity at the high concentration of nifedipine for the two preparations. There was no statistically significant difference in nifedipine oxidation by two preparations of CYP3A5.11 or CYP3A5.1, suggesting low inter-experimental variation in expression and purification. Fig. 4 and Table 1 compare kinetic parameters for nifedipine oxidation by CYP3A5.11 with that of

wild type. Kinetic parameters for nifedipine metabolism by CYP3A5.11 protein exhibited a 39% decrease in the V_{max} , a 2.7-fold increase in the K_m , and a 4.3-fold decrease in the intrinsic clearance compared to wild type.

We screened 500 healthy white Dutch individuals for this novel *CYP3A5*11* polymorphism, but could not identify additional individuals with this single nucleotide polymorphism, thus resulting in an allelic frequency of 0.1% in this population.

Discussion

Genetic variation in the CYP3A genes may influence the metabolism and elimination of CYP3A substrates in humans. Since CYP3A4 and CYP3A5 have overlapping substrates, it has been difficult to determine the effect of each CYP3A genotype on *in vivo* phenotype. The variant g.6986A>G (*CYP3A5*3*) is responsible for dramatic decreases in hepatic expression of CYP3A5 protein (Kuehl et al., 2001) and is a major determinant in low CYP3A5 protein expression in the liver due to its high frequency in many populations. However, individuals having the *CYP3A5*3*3* genotype still express low amounts of CYP3A5 protein (Hustert et al., 2001; Westlind-Johnsson et al., 2003). Several studies have identified protein coding variants of CYP3A5, as well as splice variants (Jounaidi et al., 1996; Chou et al., 2001; Hustert et al., 2001; Kuehl et al., 2001; Lee et al., 2003; Solus et al., 2004). One such allele, *CYP3A5*10*, contains a F446S change in the heme-binding region in addition to the g.6986A>G change associated with the major splice variant (Lee et al., 2003), for which the recombinant CYP3A5.10 (F446S) protein exhibited a greater than 95% decrease in the intrinsic clearance for testosterone and nifedipine compared to wild type CYP3A5.1 (Lee et al., 2003).

In the present study, we identified a new *CYP3A5* variant, *CYP3A5*11*, in white Europeans containing a single base pair change coding for Tyr53Cys. We investigated metabolism of the anti-hypertensive drug nifedipine by recombinant *CYP3A5.11* protein, showing a defective variant with a 38% decrease in the V_{max} , a 2.7-fold increase in the K_m and a 4.3-fold decrease in the intrinsic clearance compared to wild-type *CYP3A5.1*. Because this allele also contained the g.6986A>G SNP, already lower amounts of functional *CYP3A5* protein are being produced (Hustert et al., 2001; Westlind-Johnsson et al., 2003). The presence of the Tyr53Cys variant therefore affects this residual *CYP3A5* activity. The exact importance of this new SNP, in the context of the *3 splice variant, needs further studies. Although we have assumed that the *3 and *11 SNPs function independently, one affecting mRNA splicing, the other decreasing the activity of residual protein formed, expression of the *CYP3A5*11* allele in a mammalian expression system might be a better way to study this combination of SNPs. However, the Tyr53Cys variant may also occur without the g.6986A>G SNP, and would then be expected to have a more profound effect on total *CYP3A5* activity. It remains to be studied whether the observed decrease in activity on nifedipine also hold true for other *CYP3A5* substrates.

CYP3A4 and CYP3A5 have 84% amino acid sequence identity: alignment of CYP3A5 Cys-53 with CYP3A4 revealed that the CYP3A5 Cys-53 was not located in the known substrate recognition sites (SRSs) or in the active site cavity of CYP3A4 (Harlow and Halpert, 1997; Domanski et al., 1998; Domanski et al., 2000; Yano et al., 2004). The region containing Cys-53, however, is well conserved in the CYP3A4 and CYP3A5 primary amino acid sequences. In the crystal structure of CYP3A4 protein, Cys-53 appears to be located around the N-terminal "A" helix (Williams et al., 2004). A notable hydrophobic region was found around the loop following helix "A" in CYP3A4, and this hydrophobic region was suggested to be mediated with the microsomal membrane interaction (Williams et al., 2004; Scott and Halpert, 2005). The change from the tyrosine, which is a hydrophobic and aromatic amino acid, to the sulphur containing hydrophilic amino acid cysteine could cause structural changes in the membrane binding regions. The Tyr-53 in CYP3A4 was reported to be one of the amino acids involved in a hydrogen-bonding network with Arg-106, Glu-374, Asp-76, Arg-372, and Asp-61 (Yano et al., 2004). CYP3A4 and CYP3A5 have identical amino acids at all these locations except that CYP3A5 contains a Glu-76. This hydrogen-bonding network has been suggested to have

an important role in the solvent access channel in an X-ray crystallography study (Yano et al., 2004). Therefore, the increased P420 and decreased catalytic activity for nifedipine by CYP3A5.11 protein is likely to result from conformational changes caused by membrane interaction and an altered hydrogen-bonding network. However, although we even used 4x reductase, we cannot exclude that the presence of P420 somehow interferes with reductase requirement of the P450 protein, thereby lowering catalytic activity in our system.

A PCR-RFLP genotyping test, developed for the detection of the g.3775 A>G SNP found in *CYP3A5*11*, detected no additional examples of this SNP in 500 genomic DNA samples from healthy Caucasians, suggesting that *CYP3A5*11* is a very rare allele in whites. One of our previous studies detected *CYP3A5*10* only in certain white ethnic groups (Adeyi) (Lee et al., 2005), and it is possible that also the *CYP3A5*11* allele is more frequent in other ethnic groups. The present genetic test with functional information will be useful for future clinical studies to link its association with other *CYP3A* SNPs, particularly in individuals who show defective metabolism of *CYP3A* substrates.

References

- Barnes HJ, Arlotto MP and Waterman MR (1991) Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in *Escherichia coli*. *Proc Natl Acad Sci U S A* **88**:5597-5601.
- Chou FC, Tzeng SJ and Huang JD (2001) Genetic polymorphism of cytochrome P450 3A5 in Chinese. *Drug Metab Dispos* **29**:1205-1209.
- Domanski TL, He YA, Harlow GR and Halpert JR (2000) Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. *J Pharmacol Exp Ther* **293**:585-591.
- Domanski TL, Liu J, Harlow GR and Halpert JR (1998) Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation. *Arch Biochem Biophys* **350**:223-232.
- Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K and Inui K (2004) CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. *Pharmacogenetics* **14**:471-478.
- Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. *Annu Rev Pharmacol Toxicol* **39**:1-17.
- Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB and Hall SD (1996) Bimodal distribution of renal cytochrome P450 3A activity in humans. *Mol Pharmacol* **50**:52-59.
- Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity. *J Biol Chem* **272**:5396-5402.
- Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P (2004) The effect of

CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. *Pharmacogenetics* **14**:147-54.

Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. *Clin Pharmacol Ther* **74**:245-54

Huang Z, Fasco MJ, Figge HL, Keyomarsi K and Kaminsky LS (1996) Expression of cytochromes P450 in human breast tissue and tumors. *Drug Metab Dispos* **24**:899-905.

Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM and Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. *Pharmacogenetics* **11**:773-779.

Janardan SK, Lown KS, Schmiedlin-Ren P, Thummel KE and Watkins PB (1996) Selective expression of CYP3A5 and not CYP3A4 in human blood. *Pharmacogenetics* **6**:379-385.

Jounaidi Y, Hyrailles V, Gervot L and Maurel P (1996) Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? *Biochem Biophys Res Commun* **221**:466-470.

Kivisto KT, Griese EU, Fritz P, Linder A, Hakkola J, Raunio H, Beaune P and Kroemer HK (1996) Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. *Naunyn Schmiedebergs Arch Pharmacol* **353**:207-212.

Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M and Strandberg T (2004) Lipid-lowering response to statins is affected by CYP3A5 polymorphism. *Pharmacogenetics* **14**:523-525.

Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM and Watkins PB (1994) CYP3A gene expression in human gut epithelium. *Pharmacogenetics* **4**:247-259.

Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C and Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. *J Clin Invest* **90**:1871-1878.

Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS and Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *Nat Genet* **27**:383-391.

Lamba JK, Lin YS, Schuetz EG and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev* **54**:1271-1294.

Lee SJ, Bell DA, Coulter S, Ghanayem B and Goldstein JA (2005) Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3 representing a new putative defective CYP3A haplotype. *J Pharmacol Exp Ther* **313**:302-309.

Lee SJ and Goldstein JA (2005) Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. *Pharmacogenomics* **6**:357-371.

Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW and Goldstein JA (2003) Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. *Pharmacogenetics* **13**:461-472.

Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and

contribution to hepatic and intestinal midazolam metabolism. *Mol Pharmacol* **62**:162-172.

Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. *Drug Metab Rev* **34**:83-448.

Saeki M, Saito Y, Nakamura T, Murayama N, Kim SR, Ozawa S, Komamura K, Ueno K, Kamakura S, Nakajima T, Saito H, Kitamura Y, Kamatani N and Sawada J (2003) Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. *Hum Mutat* **21**:653.

Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, Guzelian P, Gionela K and Watlington CO (1992) Expression of cytochrome P450 3A in amphibian, rat, and human kidney. *Arch Biochem Biophys* **294**:206-214.

Scott EE and Halpert JR (2005) Structures of cytochrome P450 3A4. *Trends Biochem Sci* **30**:5-7.

Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* **270**:414-423.

Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL and Dawson EP (2004) Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. *Pharmacogenomics* **5**:895-931.

Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. *Transplantation* **76**:1233-5

Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. *Annu Rev Pharmacol Toxicol* **38**:389-430.

- van Schaik RH, van der Heiden IP, van den Anker JN and Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. *Clin Chem* **48**:1668-1671.
- Watkins PB, Wrighton SA, Schuetz EG, Molowa DT and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. *J Clin Invest* **80**:1029-1036.
- Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. *Drug Metab Dispos* **31**:755-761.
- Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. *Drug Metab Dispos* **30**:883-891.
- Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. *Science* **305**:683-686.
- Wong M, Balleine RL, Collins M, Liddle C, Clarke CL and Gurney H (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. *Clin Pharmacol Ther* **75**:529-538.
- Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. *J Biol Chem* **279**:38091-38094.

Footnotes

a) This research was partially supported by the Intramural Research Program of NIH and NIEHS.

b) Address reprint requests to: Ron van Schaik, Department of Clinical Chemistry, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands.

c) Numbered footnotes:

¹These two authors contributed equally to the manuscript.

²Current address: Dept. Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Korea

Legends for figures

Fig. 1. Sequencing results of the sample heterozygous for g.3775 A>G SNP (*CYP3A5*11*), shown as the reverse sequence (T>C) (A) and the PCR-RFLP result of that sample (lane 1) and of 2 wild type controls as confirmed by sequencing (lanes 2 and 3) (B).

Fig. 2. Comparison of CO difference spectrum between CYP3A5.1 (A) and CYP3A5.11 (B). The recombinant cDNA containing *CYP3A5*1* wild-type and *CYP3A5*11* was constructed in pCW vector. The recombinant plasmid was transformed into *E. coli* DH5 α competent cells. After 72 hr expression, the P450 was purified using a Ni-NTA affinity column utilizing the histidine-tag and reduced CO-spectrum was recorded between 400 and 500 nm using a DW-2000 spectrophotometer. The arrow indicates the P450 peak. CYP3A5.1 exhibited a major peak at 450 nm and a small peak at 420nm. The CYP3A5.11 protein showed two major peaks at 450 and at 420 nm.

Fig. 3. Nifedipine metabolism by CYP3A5.1 and CYP3A5.11 proteins. Reactions include 4 pmol P450 protein, 16 pmol reductase, and 8 pmol

cytochrome b₅ (the ratio of P450:reductase:cytochrome b₅ = 1:4:2) in 0.1 ml reaction buffer. All values are means of triplicate experiments ± S.E. The preparation of proteins and details of reaction mixtures are described under Materials and Methods. Two different concentrations were used, 60 μM which is near the K_m value and 240 μM which is near the V_{max}. *, significantly lower (p<0.001) than CYP3A5.1 as analyzed by two-tailed Student's t-test.

Fig. 4. Catalytic profiles of nifedipine metabolism by CYP3A5.1 (closed circles) and CYP3A5.11 (open circles). The preparation of proteins and details of reaction mixtures and kinetics are described under Materials and Methods. All reactions were performed with spectrally determined P450 (4 pmol), 16 pmol reductase, and 8 pmol cytochrome b₅ (the ratio of P450:reductase:cytochrome b₅ = 1:4:2) in 0.1 ml reaction buffer for 10 min. All values plotted are means of triplicate experiments ± S.E.


Table 1. Kinetic properties of nifedipine metabolism between CYP3A5.1 and CYP3A5.11^a

P450s	V _{max} (nmol/min/nmol P450)	K _m (μ M)	CL _{int} (ml/min/nmol P450)
CYP3A5.1	144.1 \pm 2.5	44.1 \pm 2.6	3.23
CYP3A5.11	88.2 \pm 2.6 (\downarrow 39%) ^b	118.7 \pm 8.8 (\uparrow 2.7x) ^b	0.74 (\downarrow 4.3x) ^b

^a The best fit of data was determined by the required parameters using GraphPad Prism 4.0 (GraphPad Software, Inc., San Diego CA, 2003). All data were from triplicate measurements \pm S. E. Purified P450s were determined by the Soret band at 450 nm. The amount of P450 (not P420 form) was considered in the ratio of mixture (P450:reductase:b5=1:4:2). Data were obtained from 4 pmol P450 per reaction with nifedipine concentrations of 10, 20, 40, 60, 120, 240, 480 μ M. ^b Fold and % difference compared to values of wild type.

Fig-1.

A



B




Fig. 2





Fig. 3




Fig.4

